ストックスクリーナーアプリを入手
4.55
2.71%
0.12
前日終値:
$4.43
開ける：
$4.49
24時間の取引高:
4.94M
Relative Volume:
2.74
時価総額：
$898.80M
収益：
$191.45M
当期純損益:
$160.72M
株価収益率:
5.5319
EPS:
0.8225
ネットキャッシュフロー:
$-34.44M
1週間 パフォーマンス:
+6.06%
1か月 パフォーマンス:
+9.11%
6か月 パフォーマンス:
+0.22%
1年 パフォーマンス:
+31.12%
1日の値動き範囲:
$4.46
$4.65
1週間の範囲:
$4.25
$4.65
52週間の値動き範囲:
$3.04
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.55 | 898.80M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arbutus Biopharma Corp (ABUS) Institutional Confidence - TradingKey
Arbutus Biopharma Corp (ABUS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arbutus Biopharma Corp (ABUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ABUS Stock Price, Quote & Chart - ChartMill
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results - Insider Monkey
Arbutus Biopharma (ABUS) director awarded fully vested options on 78,800 shares - Stock Titan
Director at Arbutus Biopharma (ABUS) receives 78,800 fully vested stock options - Stock Titan
Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case - Law360
ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor - Stock Titan
Arbutus Posts Profit After Moderna Patent Settlement - MyChesCo
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart
Arbutus Biopharma Corporation 8-K Filing: Company Details, Financial Data, and NASDAQ Listing (May 2026) - Minichart
Is Arbutus Biopharma (ABUS) Overvalued After Q1 2026 Earnings Be - GuruFocus
Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 E - GuruFocus
Arbutus Biopharma Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Arbutus Biopharma earnings beat by $0.91, revenue topped estimates - Investing.com
Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87— 10-Q Summary - TradingView
Arbutus: Q1 Earnings Snapshot - WKYC
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan
Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge - Stock Titan
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - Stock Titan
Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS) - Seeking Alpha
TradingKey - TradingKey
MSN Money - MSN
Arbutus Biopharma Corporation (ABUS) Stock Analysis: Exploring a 20% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
Whitefort lifts Arbutus (ABUS) economic stake to 9.8% - Stock Titan
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran - Insider Monkey
Arbutus Drug Candidate Receives FDA Fast Track Designation - MyChesCo
ABUS (Arbutus Biopharma) Other Liabilities for Banks - GuruFocus
FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -
Arbutus (ABUS) Stock: Stability Assessment (Momentum Fading) 2026-04-20Trending Momentum Stocks - newser.com
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Insider Monkey
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus
Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus
Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed - Quiver Quantitative
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):